
    
      A Phase I, Double blind, Placebo-controlled, safety and tolerability study of ZP1848
      administered as Ascending single Dose, SUBCUTANEOUS bolus injections in healthy SUBJECTS
      followed by a Multiple Dose cohort of patients with stable Crohn's disease in remission
    
  